Osama A. Abulseoud, M.D.

Osama A. Abulseoud, M.D., of Mayo Clinic in Rochester, Minn., chose to study clinical and translational research because he hopes to make a difference for people with mental illness and dependency issues.

"I'm convinced that translational research is the only way to guide our current clinical practice and bring us closer to preventing or individualizing the treatment of mental illness," he says.

In his research, he hopes to use deep brain stimulation to find a new treatment for certain difficult-to-treat cases of alcoholism. He and his colleagues are working to better understand the underlying neurobiology of addiction and how targets, such as glutamate, can be modified by deep brain stimulation in animal models of alcohol dependence. That knowledge, Dr. Abulseoud believes, will lead to testing deep brain stimulation and other glutamate modulators as novel treatments for alcoholism.

Mayo Clinic's multidisciplinary and collegial culture make this kind of translational research possible, Dr. Abulseoud says. "Mayo Clinic is the perfect place for this to happen because we can assemble a team of the best minds in addiction psychiatry, molecular pharmacology, neurosurgery and biomedical engineering to find the best ways to address each patient's needs," he explains.

Dr. Abulseoud is excited about his future as a KL2 scholar, saying, "I have an amazing opportunity to learn research methodologies and be guided by experienced mentors." Further, he is looking forward to becoming an independent investigator and leading his own multidisciplinary team of researchers in the search for a novel treatment for alcoholism.

See Dr. Abulseoud's publications on PubMed.


  • April 20, 2012
  • PRO857261